Press Releases - Archive



Shareholder Tools


 
Press Releases - Archive
Date Title and Summary View
Mar 30, 2017 SOUTH SAN FRANCISCO, Calif., March 30, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the Company will be presenting at Needham & Company's 16th Annual Hea...
Mar 29, 2017 -- Data suggest high prevalence of CRE with rapid rate of increase -- -- Company's late-stage candidate, plazomicin, may provide an important new option in treating MDR infections, including those caused by CRE -- SOUTH SAN FRANCISCO, Calif., March 29, 2017 (GLOBE NEWSWIRE) -- ...
Mar 14, 2017 Achieved positive results in Phase 3 EPIC and CARE clinical trials of plazomicin; NDA submission planned for the second half of 2017 Unveiled new orally-administered antibacterial clinical candidate, C-Scape, to be evaluated in complicated urinary tract infections (cUTI) ...
Mar 6, 2017 SOUTH SAN FRANCISCO, Calif., March 06, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it will report its fourth quarter 2016 financial results on Tues...
Mar 2, 2017 -- Company presentation scheduled for March 7th, 2017 at 9:20 a.m. ET -- SOUTH SAN FRANCISCO, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infectio...
Mar 1, 2017 -- Plazomicin NDA submission planned for the second half of 2017 -- -- Plan to initiate clinical trial of orally-administered antibacterial candidate for ESBL+ infections, C-Scape, in 2017 -- -- Advances in research expand unique pipeline of therapeutic candidates tar...
Feb 28, 2017 SOUTH SAN FRANCISCO, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company discovering and developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that on February 27, 2017, the Company's board of directors grante...
Feb 27, 2017 SOUTH SAN FRANCISCO, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company discovering and developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced the addition of Ms. Janet Dorling as Chief Commercial Officer effe...
Feb 23, 2017 SOUTH SAN FRANCISCO, Calif., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company discovering and developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced the promotions of Blake Wise to President and Chief Operating Offi...
Feb 22, 2017 Strategic milestone achieved in TDM assay developmentThermo Fisher Scientific to develop and then commercialize its assay for measuring the concentration of plazomicinSOUTH SAN FRANCISCO, Calif., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage ...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase